Market Introduction
RNA interference (RNAi) is a vital biological process in which RNA molecules inhibit gene expression or translation, by neutralizing targeted mRNA molecules. RNAi is an essential research tool in cell culture and living organisms because synthetic dsRNA introduced into cells can induce the suppression of specific genes of interest. RNAi may be used for large-scale screens that orderly shutdown each gene in the cell, which can help to know the components necessary for a particular cellular event such as cell division. The pathway is also used as a practical tool in medicine, biotechnology, and insecticides.
Market Overview and Dynamics
The North AmericaRNAi therapeuticsmarket is expected to reach US$ 598.60 million in 2027 from US$ 302.77 million in 2019. The market is anticipated to grow at a CAGR of 9.0% during 2019–2027.The growth of the market is attributed to some key driving factors such as growing investments in RNAi therapies and rising prevalence of infectious diseases & chronic conditions. However, , high cost of RNAi therapy development is expected to obstruct the growth of the market to a certain extent during the forecast years.
Key Market Segments
In terms of molecule type, the small interfering RNAs (siRNA) segment accounted for the largest share of the North America RNAi therapeuticsmarket in 2019.In terms of route of administration, the pulmonary delivery segment accounted for the largest share of the North America RNAi therapeuticsmarket in 2019.In terms of application, oncology segment accounted for the largest share of the North America RNAi therapeuticsmarket in 2019.In terms of end user, research and academic laboratoriessegment accounted for the largest share of the North America RNAi therapeutics market in 2019
Major Sources and Companies Listed
Several major primary and secondary sources associated with the North America RNAi therapeuticsmarket report are theWorld Health Organization (WHO), National Cancer Institute (NCI),Centers of Disease Control and Prevention (CDC),Asthma and Allergy Foundation of America,American Lung Association,the American Cancer Society (ACS), and others.
Reasons to buy report
NORTH AMERICA RNAI THERAPEUTICSMARKET SEGMENTATION
By Molecule Type
By Route of Administration
By Application
By End User
By Country
Company Profiles
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 302.77 Million |
| Market Size by 2027 | US$ 598.60 Million |
| CAGR (2019 - 2027) | 9.0% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By Molecule Type
|
| Regions and Countries Covered |
North America
|
| Market leaders and key company profiles |
|
The North America RNAi Therapeutics Market is valued at US$ 302.77 Million in 2019, it is projected to reach US$ 598.60 Million by 2027.
As per our report North America RNAi Therapeutics Market, the market size is valued at US$ 302.77 Million in 2019, projecting it to reach US$ 598.60 Million by 2027. This translates to a CAGR of approximately 9.0% during the forecast period.
The North America RNAi Therapeutics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America RNAi Therapeutics Market report:
The North America RNAi Therapeutics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America RNAi Therapeutics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America RNAi Therapeutics Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America RNAi Therapeutics Market
